Stock Track | Intellia Therapeutics Soars 16% Pre-Market on Promising Drug Data, Bullish Analyst Outlook

Stock Track2024-11-18

Intellia Therapeutics (NTLA) stock surged over 16% in pre-market trading on Monday, fueled by renewed investor optimism over the company's promising drug candidate Nex-Z and a bullish analyst report from JonesTrading.

On November 13th, JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on NTLA stock, citing promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook. Nex-Z is a gene editing therapy being developed by Intellia using CRISPR technology for the treatment of various genetic disorders.

Intellia Therapeutics is a leading player in the gene editing field, focused on developing curative therapeutics using its proprietary CRISPR/Cas9 platform. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects, driving the significant pre-market rally in NTLA shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101742669?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101742669","market":"hk","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Soars 16% Pre-Market on Promising Drug Data, Bullish Analyst Outlook","media":"Stock Track","content":"<p>Intellia Therapeutics (NTLA) stock surged over 16% in pre-market trading on Monday, fueled by renewed investor optimism over the company's promising drug candidate Nex-Z and a bullish analyst report from JonesTrading.</p>\n\n<p>On November 13th, JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on NTLA stock, citing promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook. Nex-Z is a gene editing therapy being developed by Intellia using CRISPR technology for the treatment of various genetic disorders.</p>\n\n<p>Intellia Therapeutics is a leading player in the gene editing field, focused on developing curative therapeutics using its proprietary CRISPR/Cas9 platform. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects, driving the significant pre-market rally in NTLA shares.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Soars 16% Pre-Market on Promising Drug Data, Bullish Analyst Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Soars 16% Pre-Market on Promising Drug Data, Bullish Analyst Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-18 17:06 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics (NTLA) stock surged over 16% in pre-market trading on Monday, fueled by renewed investor optimism over the company's promising drug candidate Nex-Z and a bullish analyst report ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1101742669","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101742669","pubTimestamp":1731920784,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics  stock surged over 16% in pre-market trading on Monday, fueled by renewed investor optimism over the company's promising drug candidate Nex-Z and a bullish analyst report from JonesTrading.On November 13th, JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on NTLA stock, citing promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook. Nex-Z is a gene editing therapy being developed by Intellia using CRISPR te","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"Intellia Therapeutics股价盘前飙升16%，原因是药物数据乐观，分析师前景乐观","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics (NTLA) stock surged over 16% in pre-market trading on Monday, fueled by renewed investor optimism over the company's promising drug candidate Nex-Z and a bullish analyst report from JonesTrading.\nOn November 13th, JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on NTLA stock, citing promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook. Nex-Z is a gene editing therapy being developed by Intellia using CRISPR technology for the treatment of various genetic disorders.\nIntellia Therapeutics is a leading player in the gene editing field, focused on developing curative therapeutics using its proprietary CRISPR/Cas9 platform. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects, driving the significant pre-market rally in NTLA shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101742669"}